Wedbush Analysts Increase Earnings Estimates for Apellis Pharmaceuticals, Inc. (NASDAQ:APLS)

Apellis Pharmaceuticals, Inc. (NASDAQ:APLS) – Stock analysts at Wedbush upped their FY2027 earnings estimates for shares of Apellis Pharmaceuticals in a research report issued to clients and investors on Friday, August 9th. Wedbush analyst L. Chico now forecasts that the company will earn $4.88 per share for the year, up from their previous estimate of $4.63. Wedbush has a “Neutral” rating and a $41.00 price target on the stock. The consensus estimate for Apellis Pharmaceuticals’ current full-year earnings is ($1.14) per share. Wedbush also issued estimates for Apellis Pharmaceuticals’ FY2028 earnings at $5.61 EPS.

Apellis Pharmaceuticals (NASDAQ:APLS) last posted its quarterly earnings results on Thursday, August 1st. The company reported ($0.30) EPS for the quarter, beating the consensus estimate of ($0.33) by $0.03. The firm had revenue of $199.70 million during the quarter, compared to analysts’ expectations of $190.89 million. Apellis Pharmaceuticals had a negative return on equity of 138.32% and a negative net margin of 52.99%. The business’s revenue for the quarter was up 110.2% on a year-over-year basis. During the same quarter last year, the firm earned ($1.02) earnings per share.

Several other research firms have also recently issued reports on APLS. Citigroup cut their price objective on shares of Apellis Pharmaceuticals from $67.00 to $60.00 and set a “buy” rating for the company in a research report on Wednesday, May 8th. Piper Sandler initiated coverage on shares of Apellis Pharmaceuticals in a research report on Friday, May 31st. They set a “neutral” rating and a $46.00 price target on the stock. UBS Group lowered their price objective on Apellis Pharmaceuticals from $85.00 to $83.00 and set a “buy” rating for the company in a research report on Friday, August 9th. Mizuho reduced their target price on Apellis Pharmaceuticals from $60.00 to $52.00 and set a “neutral” rating on the stock in a research report on Monday, April 29th. Finally, The Goldman Sachs Group increased their price target on Apellis Pharmaceuticals from $66.00 to $74.00 and gave the stock a “buy” rating in a report on Friday, August 9th. Four investment analysts have rated the stock with a hold rating, eleven have assigned a buy rating and one has given a strong buy rating to the stock. According to MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and a consensus target price of $71.69.

Apellis Pharmaceuticals Stock Down 1.2 %

Shares of APLS opened at $35.72 on Monday. The stock has a fifty day simple moving average of $38.62 and a two-hundred day simple moving average of $49.27. The company has a quick ratio of 3.02, a current ratio of 5.08 and a debt-to-equity ratio of 1.73. The company has a market capitalization of $4.34 billion, a PE ratio of -10.32 and a beta of 0.88. Apellis Pharmaceuticals has a 52-week low of $29.79 and a 52-week high of $73.80.

Institutional Trading of Apellis Pharmaceuticals

A number of large investors have recently made changes to their positions in APLS. Norges Bank acquired a new stake in shares of Apellis Pharmaceuticals in the 4th quarter valued at $56,640,000. Price T Rowe Associates Inc. MD boosted its position in shares of Apellis Pharmaceuticals by 38.0% during the 4th quarter. Price T Rowe Associates Inc. MD now owns 2,460,339 shares of the company’s stock worth $147,277,000 after acquiring an additional 677,098 shares in the last quarter. Iron Triangle Partners LP purchased a new stake in Apellis Pharmaceuticals during the first quarter worth approximately $32,329,000. Fiera Capital Corp boosted its holdings in Apellis Pharmaceuticals by 47.7% in the second quarter. Fiera Capital Corp now owns 1,401,190 shares of the company’s stock valued at $53,750,000 after purchasing an additional 452,753 shares in the last quarter. Finally, Frazier Life Sciences Management L.P. increased its stake in Apellis Pharmaceuticals by 44.2% in the fourth quarter. Frazier Life Sciences Management L.P. now owns 885,165 shares of the company’s stock valued at $52,986,000 after purchasing an additional 271,122 shares during the last quarter. 96.29% of the stock is currently owned by hedge funds and other institutional investors.

Insider Activity

In related news, Director A. Sinclair Dunlop sold 37,000 shares of the business’s stock in a transaction on Friday, June 21st. The stock was sold at an average price of $39.24, for a total transaction of $1,451,880.00. Following the completion of the transaction, the director now directly owns 136,998 shares of the company’s stock, valued at approximately $5,375,801.52. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Insiders own 6.80% of the company’s stock.

About Apellis Pharmaceuticals

Apellis Pharmaceuticals, Inc, a commercial-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutic compounds through the inhibition of the complement system for autoimmune and inflammatory diseases. It offers EMPAVELI for the treatment of paroxysmal nocturnal hemoglobinuria, C3 glomerulopathy and immune complex membranoproliferative glomerulonephritis, and hematopoietic stem cell transplantation-associated thrombotic microangiopathy; and SYFOVRE for treating geographic atrophy secondary to age-related macular degeneration and geographic atrophy (GA).